German Reimbursement Dossiers Look Trickier After Rejection Of Eisai’s Fycompa
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai’s novel epilepsy drug Fycompa will have a tough time qualifying for reimbursement in Germany after the cost-effectiveness regulator IQWiG said the manufacturer did not stick to HTA guidance on comparator selection.
You may also be interested in...
Benlysta And Fampyra Fail to Make Headway As IQWiG Tightens Comparator Screw
Germany’s health technology evaluator’s rejection of GSK’s Benlysta and Biogen Idec’s Fampyra could force companies to design separate trials for authorization and HTA assessment.
Industry Is Adapting To New Pricing Reality, Says GSK Chief Andrew Witty
Andrew Witty shines a positive light on value-based pricing and adds his voice to calls for harmonized HTAs across Europe.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.